NVCR has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NVCR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-05-14), NovoCure's current share price is $20.32. NovoCure's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $2.97. NovoCure's Cyclically Adjusted PB Ratio for today is 6.84.
The historical rank and industry rank for NovoCure's Cyclically Adjusted PB Ratio or its related term are showing as below:
During the past years, NovoCure's highest Cyclically Adjusted PB Ratio was 6.06. The lowest was 4.07. And the median was 4.78.
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
NovoCure's adjusted book value per share data for the three months ended in Mar. 2024 was $3.340. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $2.97 for the trailing ten years ended in Mar. 2024.
The historical data trend for NovoCure's Cyclically Adjusted PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NovoCure Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Cyclically Adjusted PB Ratio | Get a 7-Day Free Trial | - | - | - | 5.04 | 5.27 |
For the Medical Devices subindustry, NovoCure's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, NovoCure's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where NovoCure's Cyclically Adjusted PB Ratio falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
NovoCure's Cyclically Adjusted PB Ratio for today is calculated as
Cyclically Adjusted PB Ratio | = | Share Price | / | Cyclically Adjusted Book per Share |
= | 20.32 | / | 2.97 | |
= | 6.84 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NovoCure's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:
For example, NovoCure's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:
Adj_Book | = | Book Value per Share | / | CPI of Mar. 2024 (Change) | * | Current CPI (Mar. 2024) |
= | 3.34 | / | 129.4194 | * | 129.4194 | |
= | 3.340 |
Current CPI (Mar. 2024) = 129.4194.
NovoCure Quarterly Data
Book Value per Share | CPI | Adj_Book | |
201406 | 0.000 | 100.560 | 0.000 |
201409 | 0.000 | 100.428 | 0.000 |
201412 | 1.357 | 99.070 | 1.773 |
201503 | 0.000 | 99.621 | 0.000 |
201506 | 1.745 | 100.684 | 2.243 |
201509 | 1.466 | 100.392 | 1.890 |
201512 | 2.994 | 99.792 | 3.883 |
201603 | 2.611 | 100.470 | 3.363 |
201606 | 2.176 | 101.688 | 2.769 |
201609 | 1.845 | 101.861 | 2.344 |
201612 | 1.635 | 101.863 | 2.077 |
201703 | 1.463 | 102.862 | 1.841 |
201706 | 1.326 | 103.349 | 1.660 |
201709 | 1.306 | 104.136 | 1.623 |
201712 | 1.269 | 104.011 | 1.579 |
201803 | 1.174 | 105.290 | 1.443 |
201806 | 1.212 | 106.317 | 1.475 |
201809 | 1.236 | 106.507 | 1.502 |
201812 | 1.204 | 105.998 | 1.470 |
201903 | 1.321 | 107.251 | 1.594 |
201906 | 1.624 | 108.070 | 1.945 |
201909 | 1.924 | 108.329 | 2.299 |
201912 | 2.188 | 108.420 | 2.612 |
202003 | 2.411 | 108.902 | 2.865 |
202006 | 2.651 | 108.767 | 3.154 |
202009 | 3.018 | 109.815 | 3.557 |
202012 | 4.657 | 109.897 | 5.484 |
202103 | 3.606 | 111.754 | 4.176 |
202106 | 3.833 | 114.631 | 4.327 |
202109 | 3.980 | 115.734 | 4.451 |
202112 | 3.948 | 117.630 | 4.344 |
202203 | 4.169 | 121.301 | 4.448 |
202206 | 4.217 | 125.017 | 4.366 |
202209 | 4.244 | 125.227 | 4.386 |
202212 | 4.200 | 125.222 | 4.341 |
202303 | 4.070 | 127.348 | 4.136 |
202306 | 3.899 | 128.729 | 3.920 |
202309 | 3.688 | 129.860 | 3.676 |
202312 | 3.385 | 129.419 | 3.385 |
202403 | 3.340 | 129.419 | 3.340 |
Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
Thank you for viewing the detailed overview of NovoCure's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Pritesh Shah | officer: Chief Commercial Officer | C/O NOVOCURE INC., 20 VALLEY STREAM PARKWAY, SUITE 300, MALVERN PA 19355 |
Michal Nath Puri | officer: Chief Human Resources Officer | BUSINESS VILLAGE D4, PARK 6/PLATZ10, ROOT V8 6039 |
Wilhelmus Cm Groenhuysen | officer: Chief Financial Officer | C/O NAVTEQ CORPORATION, 222 MERCHANDISE MART STE 900, CHICAGO IL 60654 |
Ashley Cordova | officer: Chief Financial Officer | 20 VALLEY STREAM PARKWAY,, SUITE 300, MALVERN PA 19355 |
Arye Barak Ben | officer: General Counsel | TOPAZ BUILDING, 4TH FLOOR, MATAM CENTER, PO BOX 15022, SH'AR HACARMEL, HAIFA L3 31905 |
Timothy J Scannell | director | 2825 AIRVIEW BOULEVARD, KALAMAZOO MI 49002 |
Kristin Stafford | director | 1550 LIBERTY RIDGE DRIVE, SUITE 115, WAYNE PA 19087 |
Frank X Leonard | officer: President, CNS Cancers US | 20 VALLEY STREAM PARKWAY,, SUITE 300, MALVERN PA 19355 |
William Patrick Burke | officer: Chief Human Resources Officer | 195 COMMERCE WAY, PORTSMOUTH NH 03801 |
Uri Weinberg | officer: Chief Innovation Officer | NOVOCURE INC., 20 VALLEY STREAM PARKWAY, SUITE 300, MALVERN PA 19355 |
Allyson J Ocean | director | 1550 LIBERTY RIDGE DRIVE, SUITE 115, WAYNE PA 19087 |
Asaf Danziger | director, officer: Chief Executive Officer | 5 NACHUM CHAT ST., TIRAT HACARMEL L3 5112302 |
Ely Benaim | officer: Chief Medical Officer | C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD, SUITE 455, ROCKVILLE MD 20850 |
William F Doyle | director, 10 percent owner | |
Jeryl L Hilleman | director | C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025 |
From GuruFocus
By Business Wire • 11-28-2023
By Business Wire • 08-17-2023
By Business Wire • 01-08-2024
By Business Wire • 10-12-2023
By Business Wire • 08-25-2023
By Business Wire • 10-15-2023
By GuruFocus Research • 08-28-2023
By GuruFocus Research • 10-26-2023